4-Aminopyridine Toxicity: A Case Report and Review of the Literature

Journal of Medical Toxicology

Volumn 8, Issue 3, 2012, Pages 314-321

  King, Andrew M ^a   Menke, Nathan B ^a   Katz, Kenneth D ^a   Pizon, Anthony F ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

4 Aminopyridine; Case report; Overdose; Toxicity

Indexed keywords

4 AMINOPYRIDINE; BENZODIAZEPINE; DIAZEPAM; DIPHENHYDRAMINE; INFUSION FLUID; LORAZEPAM;

ADULT; AGITATION; ARTICLE; CASE REPORT; CHOREOATHETOSIS; DELIRIUM; DIAPHORESIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG INTOXICATION; DRUG OVERDOSE; DYSTONIA; ELECTROCARDIOGRAM; EMERGENCY WARD; ENDOTRACHEAL INTUBATION; HUMAN; INTENSIVE CARE UNIT; MALE; MUCOSAL DRYNESS; MULTIPLE SCLEROSIS; PHYSICAL EXAMINATION; PUPIL REFLEX; RESTLESSNESS; SINUS TACHYCARDIA; SLURRED SPEECH; TENDON REFLEX; TREMOR;

4-AMINOPYRIDINE; ADULT; BENZODIAZEPINES; DRUG OVERDOSE; HUMANS; MALE; MULTIPLE SCLEROSIS; PAROXETINE; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84865739010     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-012-0248-9     Document Type: Article

References (65)

1. Schafer EW Jr, Brunton RB, Cunningham DJ (1978) A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol App Pharmacol 26: 532-538.
2. Bischoff K, Morgan S, Chelsvig J, Spencer D (2001) 4-Aminopyridine poisoning of crows in the Chicago area. Vet Hum Toxicol 43(6): 350-352.
3. Buyukuysal RL, Wurtman RJ (1990) 4-Aminopyridine increases acetylcholine release without diminishing membrane phosphatidylcholine. J Neurochem 54(4): 1302-1309.
4. Damsma G, Biessels PT, Westerink BH et al (1988) Differential effects of 4-aminopyridine and 2, 4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis. Eur J Pharmacol 145(1): 15-20.
5. Jin S, Fredholm BB (1994) Role of NMDA, AMPA and kainate receptors in mediating glutamate- and 4-AP-induced dopamine and acetylcholine release from rat striatal slices. Neuropharmacology 33(9): 1039-1048.
6. Folgering H, Rutten J, Agoston S (1979) Stimulation of phrenic nerve activity by an acetylcholine releasing drug: 4-aminopyridine. Pfluger Arch 379: 181-185.
7. Vizi ES, van Dijk J, Foldes FF (1977) The effect of 4-aminopyridine on acetylcholine release. J Neural Transm 41: 265-274.
8. Boerma CE, Rommes JH, van Leeuwen RB, Bakker J (1995) Cardiac arrest following an iatrogenic 3, 4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J Toxicol Clin Toxicol 33(3): 249-251.
9. Maddison P, Newsom-Davis J (2005) Treatment for Lambert Eaton myasthenic syndrome. Cochrane Database Syst Rev 2: CD003279.
10. Lundh H, Nilsson O, Rosén I (1979) Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 42(2): 171-175.
11. Chang FC, Bauer RM, Benton BJ et al (1996) 4-Aminopyridine antagonizes saxitoxin-and tetrodotoxin-induced cardiorespiratory depression. Toxicon 34(6): 671-690.
12. Ball AP, Hopkinson RB, Farrell ID et al (1979) Human botulism caused by Clostridium botulinum type E: The Birmingham outbreak. Q J Med 48: 473-491.
13. Simpson LL (1986) A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect Immun 52(3): 858-862.
14. Sherratt RM, Bostock H, Sears TA (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 283: 570-572.
15. Smith KJ, Felts PA, John GR (2000) Effects of 4- aminopyridine on demyelinated axons, synapses and muscle tension. Brain 123(1): 171-184.
16. Blight AR, Toombs JP, Bauer MS, Widmer WR (1991) The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 8: 103-119.
17. Blight AR, Gruner JA (1987) Augmentation by 4- aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 82: 145-159.
18. Grijalva I, Guízar-Sahagún G, Castañeda-Hernández G et al (2003) Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Pharmacotherapy 23(7): 823-834.
19. Segal JL, Pathak MS, Hernandez JP et al (1999) Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: long-term, controlled trial. Pharmacotherapy 19(6): 713-723.
20. DeForge D, Nymark J, Lemaire E et al (2004) Effect of 4- aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal Cord 42: 674-685.
21. Donovan WH, Halter JA, Graves DE et al (2000) Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 38(1): 7-15.
22. van der Bruggen MA, Huisman HB, Beckerman H et al (2001) Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 248(8): 665-671.
23. Domingo A, Al-Yahya AA, Asiri Y, Eng JJ et al (2012) A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury. J Neurotrauma 29(5): 865-879.
24. Dunn J, Blight A (2011) Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 27(7): 1415-1423.
25. Goodman AD, Cohen JA, Cross A et al (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13(3): 357-368.
26. Uges DRA, Sohn YJ, Greijdanus B (1982) 4-Aminopyridine kinetics. Clin Pharmacol Ther 31: 587-593.
27. Hayes KC, Potter PJ, Hsieh JT et al (2004) Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 85(1): 29-34.
28. Magdalan J (2003) New treatment methods in verapamil poisoning: experimental studies. Pol J Pharmacol 55(3): 425-432.
29. Agoston S, Maestrone E, van Hezik EJ et al (1984) Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest 73(5): 1291-1296.
30. Tuncok Y, Apaydin S, Gelal A et al (1998) The effects of 4-aminopyridine and Bay K 8644 on verapamil-induced cardiovascular toxicity in anesthetized rats. J Toxicol Clin Toxicol 36(4): 301-307.
31. Gay R, Algeo S, Lee RJ et al (1986) Treatment of verapamil toxicity in intact dogs. J Clin Invest 77(6): 1805-1811.
32. Graudins A, Wong KK (2010) Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning. J Med Toxicol 6(2): 85-93.
33. Magdalan J, Kochman K, Antończyk A et al (2003) Successful treatment by 4-aminopyridine of three cases of severe verapamil poisoning. Przegl Lek 60(4): 271-273.
34. Magdalan J, Kochman K, Smolarek M et al (2003) Severe felodipine and theophylline poisoning successfully treated by 4-aminopyridine: a case report. Przegl Lek 60(4): 268-270.
35. Wilffert B, Boskma RJ, van der Voort PH et al (2007) 4-Aminopyridine (fampridine) effectively treats amlodipine poisoning: a case report. J Clin Pharm Ther 32(6): 655-657.
36. Fiszer M, Kołaciński Z, Rechciński T (2007) The application of 4-aminopyridine in calcium channel inhibitors acute poisoning. Przegl Lek 64(4-5): 293-297.
37. Klein L, Hopkins J (1981) Behavioral and cardiorespiratory responses to 4-aminopyridine in healthy awake horses. Am J Vet Res 42(9): 1655-1657.
38. Ray AC, Dwyer JN, Fambro GW, Reagor JC (1978) Clinical signs and chemical confirmation of aminopyridine poisoning in horses. Am J Vet Res 39(2): 329-331.
39. Spyker DA, Lynch C, Shabanowitz J, Sinn JA (1980) Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 16: 487-497.
40. Goodman AD, Brown TR, Cohen JA et al (2008) Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71: 1134-1141.
41. Stork CM, Hoffman RS (1994) Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 32: 583-587.
42. Pickett TA, Enns R (1996) Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 3: 382-385.
43. Smeets JW, Kunst MW (1995) Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 139(51): 2667-2669.
44. Velez L, Shirazi F, Goto C et al (2003) Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion in a healthy pediatric patient. Pediatrics 111: e82-e84.
45. Johnson NC, Morgan MW (2006) An unusual case of 4-aminopyridine toxicity. J Emerg Med 30: 175-177.
46. Burton JM, Bell CM, Walker SE et al (2008) 4-Aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 71: 1833-1834.
47. De Cauwer H, De Wolf P, Couvreur F et al (2009) An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 109: 40-41.
48. Badruddin A, Menon RS, Reder AT (2009) 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 72(12): 1100-1101.
49. Schwam E (2009) Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 41(1): 51-54.
50. Hayes KC, Katz MA, Devane JG et al (2003) Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 43(4): 379-385.
51. Vollmer T, Henney HR (2009) Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I-II, open-label trial. Clin Ther 31(10): 2206-2214.
52. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC (1994) 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 51(3): 292-296.
53. van Diemen HA, Polman CH, van Dongen TM et al (1992) The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32(2): 123-130.
54. Korenke AR, Rivey MP, Allington DR (2008) Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother 42(10): 1458-1465.
55. Goodman AD, Brown TR, Krupp L et al (2009) Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373: 732-738.
56. Acorda therapeutics: Data on file. Integrated Summary of Safety. Fampridine-SR in patients with Multiple Sclerosis. NDA 22-250, 2009.
57. Solari A, Uitdehaag B, Guliani G et al (2003) Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2: CD001330.
58. Kelley BJ, Rodriguez M (2009) Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 23: 805-815.
59. Bever CT Jr, Young D, Anderson PA et al (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44(6): 1054-1059.
60. van Diemen HA, Polman CH, Koetsier JC et al (1993) 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 16(3): 195-204.
61. Renganathan M, Sidach S, Blight AR (2009) Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells. Arch Drug Inf 2(3): 51-57.
62. March B, Cardi T (2009) Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin Investig Drugs 18: 1807-1815.
63. Isoda WC, Segal JL (2003) Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury. Pharmacotherapy 23: 133-136.
64. Yamaguchi S, Rogawski MA (1992) Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 11: 9-16.
65. Scott LJ (2011) Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 25(8): 673-698.